367 related articles for article (PubMed ID: 20689754)
21. SRC kinase inhibitors: an update on patented compounds.
Schenone S; Brullo C; Musumeci F; Radi M; Castagnolo D
Curr Med Chem; 2011; 18(33):5061-78. PubMed ID: 22050754
[TBL] [Abstract][Full Text] [Related]
22. Src tyrosine kinase as a chemotherapeutic target: is there a clinical case?
Chen T; George JA; Taylor CC
Anticancer Drugs; 2006 Feb; 17(2):123-31. PubMed ID: 16428929
[TBL] [Abstract][Full Text] [Related]
23. Src as a Therapeutic Target in Biliary Tract Cancer.
Nam AR; Kim JW; Park JE; Bang JH; Jin MH; Lee KH; Kim TY; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
Mol Cancer Ther; 2016 Jul; 15(7):1515-24. PubMed ID: 27196758
[TBL] [Abstract][Full Text] [Related]
24. SRC inhibitors as potential therapeutic agents for human cancers.
Trevino JG; Summy JM; Gallick GE
Mini Rev Med Chem; 2006 Jun; 6(6):681-7. PubMed ID: 16787379
[TBL] [Abstract][Full Text] [Related]
25. SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy.
Johnson FM; Gallick GE
Anticancer Agents Med Chem; 2007 Nov; 7(6):651-9. PubMed ID: 18045060
[TBL] [Abstract][Full Text] [Related]
26. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model.
Park SI; Zhang J; Phillips KA; Araujo JC; Najjar AM; Volgin AY; Gelovani JG; Kim SJ; Wang Z; Gallick GE
Cancer Res; 2008 May; 68(9):3323-33. PubMed ID: 18451159
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of SRC family kinases reduces myeloid-derived suppressor cells in head and neck cancer.
Mao L; Deng WW; Yu GT; Bu LL; Liu JF; Ma SR; Wu L; Kulkarni AB; Zhang WF; Sun ZJ
Int J Cancer; 2017 Mar; 140(5):1173-1185. PubMed ID: 27798955
[TBL] [Abstract][Full Text] [Related]
28. Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors.
Araujo J; Logothetis C
Cancer Treat Rev; 2010 Oct; 36(6):492-500. PubMed ID: 20226597
[TBL] [Abstract][Full Text] [Related]
29. Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells.
Simpkins F; Jang K; Yoon H; Hew KE; Kim M; Azzam DJ; Sun J; Zhao D; Ince TA; Liu W; Guo W; Wei Z; Zhang G; Mills GB; Slingerland JM
Clin Cancer Res; 2018 Oct; 24(19):4874-4886. PubMed ID: 29959144
[No Abstract] [Full Text] [Related]
30. SRC inhibitors and angiogenesis.
Schenone S; Manetti F; Botta M
Curr Pharm Des; 2007; 13(21):2118-28. PubMed ID: 17627544
[TBL] [Abstract][Full Text] [Related]
31. Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth.
Nagaraj NS; Washington MK; Merchant NB
Clin Cancer Res; 2011 Feb; 17(3):483-93. PubMed ID: 21266529
[TBL] [Abstract][Full Text] [Related]
32. Improving the prognosis for patients with glioblastoma: the rationale for targeting Src.
de Groot J; Milano V
J Neurooncol; 2009 Nov; 95(2):151-163. PubMed ID: 19436954
[TBL] [Abstract][Full Text] [Related]
33. Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing tyrosine kinase inhibitors in small cell lung cancer cells: implication of c-Src and its inhibitor.
Ueda Y; Igishi T; Hashimoto K; Suyama H; Araki K; Sumikawa T; Takeda K; Nakazaki H; Matsunami K; Kodani M; Shigeoka Y; Matsumoto S; Shimizu E
Int J Oncol; 2009 Mar; 34(3):689-96. PubMed ID: 19212674
[TBL] [Abstract][Full Text] [Related]
34. Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib.
Coluccia AM; Cirulli T; Neri P; Mangieri D; Colanardi MC; Gnoni A; Di Renzo N; Dammacco F; Tassone P; Ribatti D; Gambacorti-Passerini C; Vacca A
Blood; 2008 Aug; 112(4):1346-56. PubMed ID: 18524994
[TBL] [Abstract][Full Text] [Related]
35. The role of Src in prostate cancer.
Fizazi K
Ann Oncol; 2007 Nov; 18(11):1765-73. PubMed ID: 17426060
[TBL] [Abstract][Full Text] [Related]
36. Src inhibitors in breast cancer therapy.
Hiscox S; Nicholson RI
Expert Opin Ther Targets; 2008 Jun; 12(6):757-67. PubMed ID: 18479222
[TBL] [Abstract][Full Text] [Related]
37. Pharmacology of Src family kinases and therapeutic implications of their modulators.
Kumar A; Jaggi AS; Singh N
Fundam Clin Pharmacol; 2015 Apr; 29(2):115-30. PubMed ID: 25545125
[TBL] [Abstract][Full Text] [Related]
38. Combining Src inhibitors and aromatase inhibitors: a novel strategy for overcoming endocrine resistance and bone loss.
Hiscox S; Barrett-Lee P; Borley AC; Nicholson RI
Eur J Cancer; 2010 Aug; 46(12):2187-95. PubMed ID: 20471823
[TBL] [Abstract][Full Text] [Related]
39. Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma.
Lue HW; Cole B; Rao SA; Podolak J; Van Gaest A; King C; Eide CA; Wilmot B; Xue C; Spellman PT; Heiser LM; Tyner JW; Thomas GV
Oncotarget; 2015 Dec; 6(42):44675-87. PubMed ID: 26625308
[TBL] [Abstract][Full Text] [Related]
40. Clinical development of SRC tyrosine kinase inhibitors in lung cancer.
Lee D; Gautschi O
Clin Lung Cancer; 2006 May; 7(6):381-4. PubMed ID: 16800962
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
